Revenue $2.91 billion $2.78 billion $2.52 billion 15.7% Net Income (non-GAAP) $1.04 billion N/A $1.10 billion (5.5%) R&D and SG&A expenses (non-GAAP) $1.21 billion N/A $984 million 22.9% Vertex ...

Vertex Pharmaceuticals beat expectations for revenue but missed on earnings. The company has two recent FDA approvals and several treatments in late-stage trials. The core CF treatments make up ...

Biotechnology company Vertex Pharmaceuticals (VRTX) reported mixed results for the fourth quarter of 2024. While revenue surpassed analyst expectations, driven by strong demand for its cystic ...

Pre-earnings options volume in Vertex is normal with calls leading puts 7:4. Implied volatility suggests the market is anticipating a move near 4.1%, or $19.25, after results are released.

Moderna ( NASDAQ: MRNA) Q4 2024 Earnings Conference Call February 14, 2025 8:00 AM ET Lavina Talukdar - Senior Vice President, Investor Relations Stephane Bancel - Chief Executive Officer Jamey Mock - ...

Vertex' portfolio has been steadily expanded with new product launches to cover the majority of CF mutations, and so it has been looking at new therapeutic categories – including T1D ...

Vertex Pharma could be close to succeeding in the long-standing quest to find an alternative to potentially addictive opioids for the treatment of pain associated with common medical procedures.

Heartland Magazine is looking for models of all ages who are willing to be featured in our annual fashion issue. We partner with area boutiques and showcase the latest fashion trends. Please ...

The conventions, requirements and content of cover letters can vary greatly depending on where in the world you apply. Even the names of these letters can differ – 'motivation letter' and 'letter of ...